Robert Bermel, MD

To close the series, Marisa McGinley, DO, presents her team’s model for predicting the risk of stopping MS therapy. Rebecca Cebull, CNP, and Robert Bermel, MD, explain why concrete, individualized risk data could change how patients and clinicians make treatment decisions.

Robert Bermel, MD, explains why progression independent of relapse activity (PIRA) is still identified only after the fact. Marisa McGinley, DO, and Rebecca Cebull, CNP, outline what clinicians can do today while targeted therapies remain on the horizon.

Pharmacogenomics plays a limited role in MS care today. Marisa McGinley, DO; Rebecca Cebull, CNP; and Robert Bermel, MD, discuss why, and how multidimensional biological profiling could one day guide therapy selection.

Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker that captures progression.

Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker that captures progression.

Cleveland Clinic's Marisa McGinley, DO; Robert Bermel, MD; and Rebecca Cebull, CNP, open the series by defining what precision medicine means in MS and how far the field has moved past a one-size-fits-all approach to treatment.

The director of the Mellen Center for MS at Cleveland Clinic talked about the ENSEMBLE study results that were presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The director of the Mellen Center for MS at Cleveland Clinic offered an overview of the State of the Science Summit that was held on November 10, 2022, featuring a panel of expert clinicians. [WATCH TIME: 4 minutes]

The importance of addressing disorders of the brain cannot be overstated, and doing so will be essential to our generation and generations to come.